Evidence map›Paper›PMID 39902037›Full record

ArticleFrontiers in immunology2024

TMBocelot: an omnibus statistical control model optimizing the TMB thresholds with systematic measurement errors.

Xin Lai, Shaoliang Wang, Xuanping Zhang, Xiaoyan Zhu, Yuqian Liu, Zhili Chang, Xiaonan Wang, Yang Shao, Jiayin Wang, Yixuan Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin Lai *School of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Shaoliang Wang *School of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xuanping ZhangSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xiaoyan ZhuSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yuqian LiuSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Zhili ChangSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Xiaonan WangSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yang ShaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Jiayin WangSchool of Computer Science and Technology, Faculty of Electronics and Information Engineering, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Yixuan WangDepartment of Biomedical Engineering, College of Automation Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor mutation burden (TMB), defined as the number of somatic mutations of tumor DNA, is a well-recognized immunotherapy biomarker endorsed by regulatory agencies and pivotal in stratifying patients for clinical decision-making. However, measurement errors can compromise the accuracy of TMB assessments and the reliability of clinical outcomes, introducing bias into statistical inferences and adversely affecting TMB thresholds through cumulative and magnified effects. Given the unavoidable errors with current technologies, it is essential to adopt modeling methods to determine the optimal TMB-positive threshold. Therefore, we proposed a universal framework, TMBocelot, which accounts for pairwise measurement errors in clinical data to stabilize the determination of hierarchical thresholds. TMBocelot utilizes a Bayesian approach based on the stationarity principle of Markov chains to implement an enhanced error control mechanism, utilizing moderately informative priors. Simulations and retrospective data from 438 patients reveal that TMBocelot outperforms conventional methods in terms of accuracy, consistency of parameter estimations, and threshold determination. TMBocelot enables precise and reliable delineation of TMB-positive thresholds, facilitating the implementation of immunotherapy. The source code for TMBocelot is publicly available at https://github.com/YixuanWang1120/TMBocelot.

Indexed as

Biomarkers, TumorModels, StatisticalMutationNeoplasmsBayes TheoremHumansImmunotherapyBiomarkers, TumorBayesian frameworkimmunotherapy endpointspairwise error controlpositive-threshold optimizationtumor mutation burden

Identifiers

PMID39902037
PMCPMC11788372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.